100 related articles for article (PubMed ID: 22334096)
1. N-succinylaspart-1-yl celecoxib is a potential colon-specific prodrug of celecoxib with improved therapeutic properties.
Lee Y; Kim J; Kim H; Kang S; Yoon JH; Kim DD; Kim YM; Jung Y
J Pharm Sci; 2012 May; 101(5):1831-42. PubMed ID: 22334096
[TBL] [Abstract][Full Text] [Related]
2. Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis.
Lee Y; Kim H; Kim W; Yoon JH; Jeong SH; Jung Y
J Drug Target; 2012 Jul; 20(6):524-34. PubMed ID: 22632102
[TBL] [Abstract][Full Text] [Related]
3. Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: a potential pharmacologic mechanism and therapeutic advantages.
Lee Y; Kim W; Hong S; Park H; Yum S; Yoon JH; Jung Y
Eur J Pharmacol; 2014 Mar; 726():49-56. PubMed ID: 24462351
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib coupled to dextran via a glutamic acid linker yields a polymeric prodrug suitable for colonic delivery.
Lee Y; Kim J; Kim W; Nam J; Jeong S; Lee S; Yoo JW; Kim MS; Jung Y
Drug Des Devel Ther; 2015; 9():4105-13. PubMed ID: 26251576
[TBL] [Abstract][Full Text] [Related]
5. Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent.
Kim W; Lee Y; Jeong S; Nam J; Lee S; Jung Y
Arch Pharm Res; 2015 Oct; 38(10):1830-8. PubMed ID: 25860026
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of N-nicotinoyl-2-{2-(2-methyl-5-nitroimidazol-1-yl)ethyloxy}-D,L-glycine as a colon-specific prodrug of metronidazole.
Kim D; Hong S; Jung S; Jung Y; Kim YM
J Pharm Sci; 2009 Nov; 98(11):4161-9. PubMed ID: 19283770
[TBL] [Abstract][Full Text] [Related]
7. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on nuclear factor-κB, an anti-inflammatory target.
Lee S; Lee Y; Kim W; Nam J; Jeong S; Yoo JW; Kim MS; Moon HR; Jung Y
Drug Des Devel Ther; 2015; 9():4227-37. PubMed ID: 26300626
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of p53 and mitochondrial signaling pathway in apoptosis by a combination of COX-2 inhibitor, Celecoxib and Dolastatin 15, a marine mollusk linear peptide in experimental colon carcinogenesis.
Piplani H; Vaish V; Rana C; Sanyal SN
Mol Carcinog; 2013 Nov; 52(11):845-58. PubMed ID: 22623379
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of sulfate conjugated metronidazole as a colon-specific prodrug of metronidazole.
Kim H; Lee Y; Yoo H; Kim J; Kong H; Yoon JH; Jung Y; Kim YM
J Drug Target; 2012 Apr; 20(3):255-63. PubMed ID: 22118327
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
13. pH-sensitive nanoparticles of curcumin-celecoxib combination: evaluating drug synergy in ulcerative colitis model.
Gugulothu D; Kulkarni A; Patravale V; Dandekar P
J Pharm Sci; 2014 Feb; 103(2):687-96. PubMed ID: 24375287
[TBL] [Abstract][Full Text] [Related]
14. Effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on serum interleukin-1beta, osteocalcin, and C-reactive protein levels in rats.
Vardar-Sengül S; Buduneli N; Buduneli E; Baylas H; Atilla G; Lappin D; Kinane DF
J Periodontol; 2006 Apr; 77(4):657-63. PubMed ID: 16584347
[TBL] [Abstract][Full Text] [Related]
15. A nitrophenyl-based prodrug type for colorectal targeting of prednisolone, budesonide and celecoxib.
Marquez Ruiz JF; Kedziora K; Pigott M; Keogh B; Windle H; Gavin J; Kelleher DP; Gilmer JF
Bioorg Med Chem Lett; 2013 Mar; 23(6):1693-8. PubMed ID: 23416011
[TBL] [Abstract][Full Text] [Related]
16. Preparation and Evaluation of Amino Acid Conjugates of Celecoxib as Prodrugs to Improve the Pharmacokinetic and Therapeutic Properties of Celecoxib.
Lee Y; Kim J; Kim W; Yoon IS; Jung Y
Pharmaceutics; 2020 Oct; 12(11):. PubMed ID: 33143357
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.
Jung Y; Kim HH; Kim H; Kong H; Choi B; Yang Y; Kim Y
Eur J Pharm Sci; 2006 May; 28(1-2):26-33. PubMed ID: 16455235
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis of murine lupus T cells induced by the selective cyclooxygenase-2 inhibitor celecoxib: molecular mechanisms and therapeutic potential.
Yang P; Zhang Y; Ping L; Gao XM
Int Immunopharmacol; 2007 Nov; 7(11):1414-21. PubMed ID: 17761345
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice.
Garcia M; Velez R; Romagosa C; Majem B; Pedrola N; Olivan M; Rigau M; Guiu M; Gomis RR; Morote J; Reventós J; Doll A
BJU Int; 2014 May; 113(5b):E164-77. PubMed ID: 24127882
[TBL] [Abstract][Full Text] [Related]
20. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.
Kawamori T; Rao CV; Seibert K; Reddy BS
Cancer Res; 1998 Feb; 58(3):409-12. PubMed ID: 9458081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
